Braz J Med Biol Res 2019; 52(8): e8443

Association between BDNF G196A (Val66Met) polymorphism and cognitive impairment in patients with Parkinson’s disease: a meta-analysis

Qian Wang ORCID logo , Jianfang Liu ORCID logo , Yikun Guo ORCID logo , Guanzhong Dong ORCID logo , Wenying Zou ORCID logo , Zhuoyou Chen ORCID logo

DOI: 10.1590/1414-431X20198443

Brain-derived neurotrophic factor (BDNF) is widely expressed in the central nervous system and prolongs the survival of dopaminergic neurons in the substantia nigra. Several studies have recently investigated the association between BDNF G196A (Val66Met), a single nucleotide polymorphism influencing cognitive processes, and cognitive impairment in Parkinson’s disease (PD), but with contradictory findings. Thus, this meta-analysis was performed to clarify the possible association. Relevant studies were identified by a systematic search of PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases. The strength of the association was evaluated using crude odds ratios and 95% confidence interval. Finally, six studies involving 532 cases and 802 controls were included. Our analyses suggested the G196A (Val66Met) polymorphism was significantly associated with cognitive impairment in PD, especially in Caucasian populations. In conclusion, BDNF G196A (Val66Met) is confirmed to be a risk factor for cognitive impairment in PD.

Association between BDNF G196A (Val66Met) polymorphism and cognitive impairment in patients with Parkinson’s disease: a meta-analysis

Comments